Exercise Plus Computer Time May Boost Seniors' Brains
TUESDAY, May 1 (HealthDay News) -- A combination of moderate
exercise and mental stimulation through computer use may help
reduce the risk of age-related memory loss more than computer use
or exercise alone, according to new research.
Arthritis in Children Linked to Infections
TUESDAY, May 1 (HealthDay News) -- Children with juvenile
arthritis have higher rates of bacterial infection when
hospitalized than children without arthritis, a new study says.
Study Downplays Risk of CT Scans
TUESDAY, May 1 (HealthDay News) -- A new study of young people
who underwent CT scans suggests that their risk of dying from a
condition related to their radiation exposure is far less than
dying from the original disease they faced.
Less-Invasive Surgery for Esophageal Cancer Might Be Safer
MONDAY, April 30 (HealthDay News) -- Besides being easier on the
patient, minimally invasive surgery to remove the esophagus of
patients with esophageal cancer can also greatly reduce the risk of
lung infection compared to traditional open surgery, a new study
Better Ways Needed to Track Drug Safety: Report
TUESDAY, May 1 (HealthDay News) -- A management plan to gather,
assess and respond to data about all medications' risks from the
time they are approved until they are no longer on the market is
needed to improve drug safety in the United States, says an
Institute of Medicine report released Tuesday.
Can Blood Test Predict Breast Cancer Risk?
TUESDAY, May 1 (HealthDay News) -- A blood test that spots
changes in a specific gene could reveal a woman's risk for breast
cancer years before the disease has a chance to develop,
For Breast Cancer Care, Radiation of Whole Breast May Be Best
TUESDAY, May 1 (HealthDay News) -- Women who receive a type of
partial-breast radiation called brachytherapy may go on to have
higher rates of breast cancer recurrence and side effects such as
breast pain and infection than women receiving whole-breast
radiation, a new study indicates.
Elelyso Approved for Gaucher Disease
TUESDAY, May 1 (HealthDay News) -- Elelyso (taliglucerase alfa)
has been approved by the U.S. Food and Drug Administration as a
long-term enzyme replacement therapy for people with a rare genetic
disorder called type 1 Gaucher disease.